Imaging a functional tumorigenic biomarker in the transformed epithelium

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 1, 2013, Pages 93-98

  LeBeau, Aaron M ^a,b   Lee, Minhee ^c   Murphy, Stephanie T ^b   Hann, Byron C ^d   Warren, Robert S ^d   Delos Santos, Romelyn ^b   Kurhanewicz, John ^b   Hanash, Samir M ^c   VanBrocklin, Henry F ^b   Craik, Charles S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer biomarker; Molecular imaging

Indexed keywords

HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1; INDIUM 111; MATRIPTASE; PROTEIN INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELLULAR DISTRIBUTION; COLON CANCER; CONTROLLED STUDY; EPITHELIUM; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MASS SPECTROMETRY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE MICROARRAY;

ANTIBODIES; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; EPITHELIAL CELLS; HUMANS; INDIUM RADIOISOTOPES; MASS SPECTROMETRY; OPTICAL IMAGING; PROTEINASE INHIBITORY PROTEINS, SECRETORY; SERINE ENDOPEPTIDASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84871969232     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1218694110     Document Type: Article

References (36)

1. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y (2006) Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 231(1):20-27. (Pubitemid 43063974)
2. Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57(1):25-40. (Pubitemid 30105328)
3. Mignatti P, Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73(1):161-195. (Pubitemid 23065437)
4. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161-174. (Pubitemid 37328786)
5. Jin JS, et al. (2006) Expression of serine protease matriptase in renal cell carcinoma: Correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters. Int J Surg Pathol 14(1):65-72.
6. Uhland K (2006) Matriptase and its putative role in cancer. Cell Mol Life Sci 63(24):2968-2978.
7. Tsai WC, et al. (2008) Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: Tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis Markers 24(2):89-99.
8. Darragh MR, Bhatt AS, Craik CS (2008) MT-SP1 proteolysis and regulation of cell-microenvironment interactions. Front Biosci 13:528-539. (Pubitemid 351599763)
9. Tripathi M, et al. (2011) Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells. Prostate 71(2):184-196.
10. Szabo R, et al. (2011) c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. Oncogene 30(17):2003-2016.
11. Oberst MD, et al. (2003) Characterization of matriptase expression in normal human tissues. J Histochem Cytochem 51(8):1017-1025. (Pubitemid 36919979)
12. Buzza MS, et al. (2010) Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine. Proc Natl Acad Sci USA 107(9):4200-4205.
13. Camerer E, et al. (2010) Local protease signaling contributes to neural tube closure in the mouse embryo. Dev Cell 18(1):25-38.
14. Parr C, Sanders AJ, Jiang WG (2010) Hepatocyte growth factor activation inhibitors: Therapeutic potential in cancer. Anticancer Agents Med Chem 10(1):47-57.
15. Saleem M, et al. (2006) A novel biomarker for staging human prostate adenocarcinoma: Overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 15(2):217-227. (Pubitemid 43342167)
16. Blum G, von Degenfeld G, Merchant MJ, Blau HM, Bogyo M (2007) Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat Chem Biol 3(10):668-677. (Pubitemid 47417706)
17. Mease RC, et al. (2008) N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F] fluorobenzyl-L-cysteine, [18F]DCFBC: A new imaging probe for prostate cancer. Clin Cancer Res 14(10):3036-3043.
18. Smith-Jones PM, et al. (2004) Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22(6):701-706. (Pubitemid 38702826)
19. Ren G, et al. (2011) Non-invasive imaging of cysteine cathepsin activity in solid tumors using a 64Cu-labeled activity-based probe. PLoS ONE 6(11):e28029.
20. LeBeau AM, Singh P, Isaacs JT, Denmeade SR (2008) Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen. Chem Biol 15(7):665-674. (Pubitemid 351957911)
21. Brown CM, et al. (2011) Peptide length and leaving-group sterics influence potency of peptide phosphonate protease inhibitors. Chem Biol 18(1):48-57.
22. Schneider EL, et al. (2012) A reverse binding motif that contributes to specific protease inhibition by antibodies. J Mol Biol 415(4):699-715.
23. Baechler S, et al. (2010) Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab. J Nucl Med 51(12):1878-1884.
24. Mease RC (2010) Radionuclide based imaging of prostate cancer. Curr Top Med Chem 10(16):1600-1616.
25. Sun J, Pons J, Craik CS (2003) Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies. Biochemistry 42(4):892-900. (Pubitemid 36159520)
26. Farady CJ, Egea PF, Schneider EL, Darragh MR, Craik CS (2008) Structure of an Fabprotease complex reveals a highly specific non-canonical mechanism of inhibition. J Mol Biol 380(2):351-360.
27. Darragh MR, et al. (2010) Tumor detection by imaging proteolytic activity. Cancer Res 70(4):1505-1512.
28. Liu H, Sadygov RG, Yates JR III (2004) A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 76(14):4193-4201. (Pubitemid 38943698)
29. Taguchi A, et al. (2011) Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 20(3):289-299.
30. Pitteri SJ, et al. (2009) Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS ONE 4(11):e7916.
31. Dangles-Marie V, et al. (2007) Establishment of human colon cancer cell lines from fresh tumors versus xenografts: Comparison of success rate and cell line features. Cancer Res 67(1):398-407. (Pubitemid 46142799)
32. Davies RJ, Miller R, Coleman N (2005) Colorectal cancer screening: Prospects for molecular stool analysis. Nat Rev Cancer 5(3):199-209. (Pubitemid 40314951)
33. Vogel LK, et al. (2006) The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals. BMC Cancer 6:176.
34. Webb SL, Sanders AJ, Mason MD, Jiang WG (2011) Type II transmembrane serine protease (TTSP) deregulation in cancer. Front Biosci 16:539-552.
35. Salazar R, et al. (2011) Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29(1):17-24.
36. Kelley RK, Wang G, Venook AP (2011) Biomarker use in colorectal cancer therapy. J Natl Compr Canc Netw 9(11):1293-1302.